Drug profile

The FDA adverse-event record for Cyclosporine (Ophthalmic)

130 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Cyclosporine (Ophthalmic). See the species affected, top reactions, and outcomes below.

130
adverse-event reports
7.7%
death-coded share
Dog
most-reported species
27
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
130
Total Reports
10
Deaths Reported
7.7%
Death Rate

Active Ingredients

Cyclosporine (Ophthalmic)

Administration Routes

OphthalmicUnknownIntraocularSubcutaneous

Species Affected

Dog 129
Cat 1

Most Affected Breeds

Shih Tzu 18
Crossbred Canine/dog 12
Lhasa Apso 8
Dachshund (unspecified) 8
Terrier - West Highland White 6
Terrier - Yorkshire 5
Pug 5
Spaniel - Cocker American 5
Poodle - Miniature 4
Retriever - Labrador 4

Most Reported Reactions

Vomiting 27
Corneal ulcer 18
Lack of efficacy - NOS 16
Neurogenic keratoconjunctivitis sicca (KCS) 16
Squinting 14
Lethargy (see also Central nervous system depression in 'Neurological') 13
Ocular discharge 13
Ataxia 12
Diarrhoea 12
Abnormal Schirmer tear test 12
Emesis 11
Decreased appetite 11

Outcome Breakdown

Recovered/Normal
48 (36.9%)
Outcome Unknown
35 (26.9%)
Ongoing
33 (25.4%)
Euthanized
7 (5.4%)
Recovered with Sequela
4 (3.1%)
Died
3 (2.3%)

Cyclosporine (Ophthalmic) Adverse Event Insights

130 reports name Cyclosporine (Ophthalmic); 10 recorded a death outcome (7.7% of reported events, not a population-level mortality rate). Active ingredient: Cyclosporine (Ophthalmic). Administration routes: Ophthalmic, Unknown, Intraocular, Subcutaneous.

By species: Dog (129 reports), Cat (1 reports). By breed: Shih Tzu (18), Crossbred Canine/dog (12), Lhasa Apso (8).

Leading clinical signs: Vomiting (27), Corneal ulcer (18), Lack of efficacy - NOS (16), Neurogenic keratoconjunctivitis sicca (KCS) (16). Outcome, 130 coded reports: Recovered/Normal leads at 36.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.